

Rev.: 2024-3-18

Recombinant Rabbit Monoclonal Antibody		Catalog#	BX50323
Product Datasheet		Clone#	BP6300
Predicted Molecular Wt:	22kDa	Purity:	ProA affinity purified IgG
Species Cross-reactivity:	Human	Form:	Liquid
Applications:	IHC-P	Swissprot ID:	P32970

Background:

CD70 is a type II transmembrane glycoprotein and a member of the tumor necrosis factor ligand superfamily (TNFSF), also known as CD27L and TNFSF7.

CD70 is normally expressed on medullary thymic epithelial cells. Its expression is induced on activated lymphoid cells (B cells, T cells and NK cells) and dendritic cells.

CD70 is closely related to the occurrence of tumors and the prognosis of patients. At present, the indications for preclinical development are mainly breast cancer, ovarian cancer, blood tumor and kidney cancer.

Subcellular location:

Membrane

Recommended Method:

Heat induced epitope retrieval with Tris-EDTA buffer (pH 9.0), primary antibody incubate at RT (18°C-25°C) for 30 minutes.

Immunogen:

Synthetic peptide. This information is proprietary to Biolynx.

Storage Buffer:

PBS 59%, Sodium azide 0.01%, Glycerol 40%, BSA 0.05%.

Storage Conditions:

-25°C to -18°C

Shipment Instructions:

Shipped on blue ice. Upon delivery store at -25°C to -18 °C. Avoid freeze / thaw cycles.


Recommended Dilution:

IHC-P: 1:100-1:200

Background References:

1. Jacobs, J. et al. (2015) Oncotarget 6, 13462-75.

2. Nolte, M.A. et al. (2009) Immunol Rev 229, 216-31.



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of renal clear cell carcinoma labelling CD70 with BP6300.

for Product QC'd by:

For research use only. Not for use in diagnostic or therapeutic applications.